Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need

  • Abbott to release limited quantities of EleCare ® branded specialty formulas
  • Product will be released immediately free of charge to children in need
  • Parents and caregivers in urgent need should contact their healthcare professionals or Abbott at +1-800-881-0876 for additional information
  • Abbott plans to restart production at the Sturgis facility on June 4 and will prioritize EleCare production, with initial EleCare product release to consumers beginning on or about June 20

Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing Abbott to release limited quantities of its EleCare ® specialty amino acid-based formulas that were previously on hold following the Feb. 17 recall of some powder infant formulas from its Sturgis, Mich. facility. The consent decree was amended at the request of Abbott and the U.S. Food and Drug Administration (FDA) to enable the company to get EleCare to children in urgent medical need. These EleCare product batches were on hold pursuant to an agreement with the FDA.

All products have been tested and meet all product release requirements. In addition, Abbott has concluded additional, enhanced testing to provide assurance the product is safe to distribute. Abbott plans to restart production at the Sturgis facility on June 4 and will prioritize EleCare production, with initial EleCare product release to consumers beginning on or about June 20 .

EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas. While Abbott has limited inventory of these products, there should be enough to fulfill current patient needs until new product is available in the coming months. The products being released are EleCare (for infants 0-12 months) and EleCare Jr (for ages one year and up).

Similac ® and Alimentum ® powder formulas that were voluntarily recalled in February are not included in this product release.

What Parents, Caregivers and Healthcare Professionals Should Do
EleCare products are used under the care of a healthcare professional. Parents and caregivers in urgent need should contact their healthcare professionals or Abbott at +1-800-881-0876 for additional information.

Abbott will fulfill requests to the best of its ability and as quickly as possible. Abbott expects to begin shipping product within the next several days. Product will be shipped directly to healthcare professionals, hospitals or consumers. Once production resumes in the Sturgis facility, Abbott will prioritize manufacturing of EleCare and other specialty and metabolic formulas to restock supplies as quickly as possible.

"Releasing this product immediately will help families impacted by the lack of availability of EleCare," said Robert B. Ford , chairman and chief executive officer, Abbott. "When we restart our Sturgis facility the first week in June, we will produce EleCare first and make enough so that several months of supply will be available."

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

Cision View original content: https://www.prnewswire.com/news-releases/abbott-to-release-elecare-amino-acid-based-formulas-to-help-meet-critical-patient-need-301554458.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded... Keep Reading...
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...

Latest Press Releases

Related News